Literature DB >> 27121095

Endoresection of large uveal melanomas: clinical results in a consecutive series of 200 cases.

Eva Biewald1, Hilke Lautner1, Mete Gök1, Gerhard Alfons Horstmann2, Wolfgang Sauerwein3, Dirk Flühs3, Norbert Bornfeld1.   

Abstract

BACKGROUND: To report eye salvaging rate, visual acuity (VA), local recurrences, complications and the potential benefit of adjuvant brachytherapy after endoresection of large uveal melanomas.
METHODS: 200 patients were included in this retrospective study. They were treated from March 1999 to December 2010 with preoperative stereotactic gamma knife radiosurgery followed by endoresection and adjuvant brachytherapy in most cases.
RESULTS: A total of 200 patients were included in this study (113 male, 87 female). Mean tumour height was 9.4 mm and the largest basal diameter ranged from 6.3 to 20 mm. The median follow-up time was 32.3 months. In 13.4% the eye was retained with a VA of 20/50 or better, in 33.6% VA was ranging from 20/400 to 20/50 and 53% had a VA of less than 20/400. In almost 90% of the cases the eye was preserved at the final visit. In 15.5% additional major surgery was required. In terms of survival 15.5% of our patients developed liver metastases during follow-up and died. Local tumour recurrence was observed in 10 out of 200 patients (5%) and was mainly treated with enucleation. The use of an adjuvant ruthenium-106 plaque did not lower the recurrence or enucleation rate significantly.
CONCLUSIONS: Eyes with a large uveal melanoma can be preserved by stereotactic radiotherapy followed by endoresection with the chance to obtain useful vision in approximately half of the cases. Adjuvant brachytherapy has no beneficial effect except a reduction of the frequency for major revision surgery. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  Choroid; Ciliary body; Neoplasia; Treatment Surgery

Mesh:

Year:  2016        PMID: 27121095     DOI: 10.1136/bjophthalmol-2015-307076

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  7 in total

Review 1.  The Interdisciplinary Diagnosis and Treatment of Intraocular Tumors.

Authors:  Norbert Bornfeld; Eva Biewald; Sebastian Bauer; Petra Temming; Dietmar Lohmann; Michael Zeschnigk
Journal:  Dtsch Arztebl Int       Date:  2018-02-16       Impact factor: 5.594

2.  Secondary endoresection for previously treated choroidal melanomas with a non-responsive course and persistent exudative retinal detachment.

Authors:  Ahmet Kaan Gündüz; Ibadulla Mirzayev
Journal:  Int J Ophthalmol       Date:  2022-02-18       Impact factor: 1.779

3.  Fatal Air Embolism after Choroidal Melanoma Endoresection without Air Infusion: A Case Report.

Authors:  Duangnate Rojanaporn; Boontip Tipsuriyaporn; Patnarin Chulalaksiriboon; Tanit Virankabutra; Sunthiti Morakul; Bertil Damato
Journal:  Ocul Oncol Pathol       Date:  2021-08-13

4.  Current molecular and clinical insights into uveal melanoma (Review).

Authors:  Matteo Fallico; Giuseppina Raciti; Antonio Longo; Michele Reibaldi; Vincenza Bonfiglio; Andrea Russo; Rosario Caltabiano; Giuseppe Gattuso; Luca Falzone; Teresio Avitabile
Journal:  Int J Oncol       Date:  2021-03-02       Impact factor: 5.650

5.  Surgical Approach in Intraocular Tumors

Authors:  Ahmet Kaan Gündüz; Ibadulla Mirzayev
Journal:  Turk J Ophthalmol       Date:  2022-04-28

6.  Short-term perfluorocarbon liquid tamponade in choroidal melanoma endoresection.

Authors:  Hany S Hamza; Ayman G Elnahry
Journal:  Int J Retina Vitreous       Date:  2022-07-06

7.  Feasibility, Method and Early Outcome of Image-Guided Volumetric Modulated Arc Radiosurgery Followed by Resection for AJCC Stage IIA-IIIB High-Risk Large Intraocular Melanoma.

Authors:  Maja Guberina; Ekaterina Sokolenko; Nika Guberina; Sami Dalbah; Christoph Pöttgen; Wolfgang Lübcke; Frank Indenkämpen; Manfred Lachmuth; Dirk Flühs; Ying Chen; Christian Hoffmann; Cornelius Deuschl; Leyla Jabbarli; Miltiadis Fiorentzis; Andreas Foerster; Philipp Rating; Melanie Ebenau; Tobias Grunewald; Nikolaos Bechrakis; Martin Stuschke
Journal:  Cancers (Basel)       Date:  2022-09-28       Impact factor: 6.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.